Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases.
Eur Neuropsychopharmacol
; 25(11): 2183-4, 2015 Nov.
Article
em En
| MEDLINE
| ID: mdl-26302763
ABSTRACT
Ketamine, a rapid-acting antidepressant and anti-suicidal agent, is thought to increase brain monoamine levels by enhancing monoamine release or inhibiting presynaptic monoamine-reuptake. Here we present two female inpatients suffering from treatment-resistant depression with recurrent severe suicidal crises receiving a combination of intravenous S-ketamine and oral tranylcypromine, which is a well-known irreversible monoamine oxidase (MAO) inhibitor. Since inhibition of monoamine-reuptake with concurrent blockade of MAO might trigger sympathomimetic crisis, this combination is considered hazardous. Nonetheless, cardiovascular parameters remained stable in both patients, while good anti-suicidal effects were observed. Hence, we put serious doubt on whether monoamine-reuptake inhibition is a relevant pharmacological effect of ketamine in humans.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tranilcipromina
/
Transtorno Depressivo Resistente a Tratamento
/
Ketamina
/
Antidepressivos
Limite:
Adult
/
Aged
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article